Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26148600 | 0.90 | KDM1A (0.54) | KDM1AALDH1A1 | |
| SCHEMBL18848696 | 0.85 | KDM1A (0.62) | KDM1AKDM4EALDH1A1ADAM17 | |
| SCHEMBL18848693 | 0.84 | KDM1A (0.61) | KDM1AKDM4EALDH1A1 | |
| SCHEMBL18848613 | 0.82 | KDM1A (0.46) | KDM1AALDH1A1 | |
| SCHEMBL18848747 | 0.79 | KDM1A (0.46) | KDM1AALDH1A1F10 | |
| SCHEMBL16455032 | 0.77 | MEN1 (0.50) | KDM1AEPHX2 | |
| SCHEMBL16455197 | 0.76 | KDM1A (0.48) | KDM1A | |
| SCHEMBL18848609 | 0.75 | KDM1A (0.47) | KDM1A | |
| SCHEMBL20781336 | 0.75 | KDM1A (0.65) | KDM1A | |
| SCHEMBL16455164 | 0.74 | KDM1A (0.65) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | KDM1A 2/4885KDM4E 20/4885ALDH1A1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.